SCHEMBL1009738

SCHEMBL1009738

COC(=O)c1cc(N)[nH]n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.65
POLB P06746 2/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.44
HCAR2 Q8TDS4 1/20 0.40
GAA P10253 1/20 0.39
ALPL P05186 2/20 0.38
MAPT P10636 2/20 0.38
CSNK2A2 P19784 1/20 0.38
KDR P35968 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
NQO2 P16083 2/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 1/20 0.38
KDM4C Q9H3R0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL14785045 0.98 MAPK1 (0.62) MAPK1POLBRAB9ANPC1MEN1
Ammonia Solution, Strong SCHEMBL1009944 0.98 MAPK1 (0.62) MAPK1POLBRAB9ANPC1MEN1
SCHEMBL14688318 0.80 MAPK1 (0.42) MAPK1POLBRAB9ANPC1HCAR2
SCHEMBL930612 0.80 KMT2A (0.52) MAPK1POLBRAB9ANPC1MEN1
SCHEMBL5028345 0.79 LMNA (0.46) MAPK1RAB9ANPC1KMT2AL3MBTL1
SCHEMBL3624738 0.78 MAPK1 (0.67) MAPK1POLBRAB9ANPC1MEN1
SCHEMBL68056 0.78 MAPK1 (1.00) MAPK1POLBRAB9ANPC1MEN1
SCHEMBL4490261 0.78 MAPK1 (0.67) MAPK1POLBRAB9ANPC1MEN1
SCHEMBL163583 0.78 MAPK1 (0.67) MAPK1POLBRAB9ANPC1MEN1
SCHEMBL19358351 0.78 MAPK1 (0.61) MAPK1POLBRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 US disclosed
WO-2025119300-A1 MYT1 KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 广东东阳光药业股份有限公司 2025-06-12 WO disclosed
CN-120118088-A Myt1 kinase inhibitor compounds, pharmaceutical compositions thereof and uses thereof 广东东阳光药业股份有限公司 2025-06-10 CN disclosed
US-20240376108-A1 SALT AND CRYSTAL FORM OF PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-11-14 US disclosed
CN-118894855-A Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-11-05 CN disclosed
CN-118894856-A Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-11-05 CN disclosed
CN-114222746-B Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-08-02 CN disclosed
US-20240199623-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS ILDONG PHARMACEUTICAL CO., LTD. (KR) 2024-06-20 US disclosed
EP-4353725-A1 SALT AND CRYSTAL FORM OF PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-04-17 EP disclosed
US-11834467-B2 Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors 1ST Biotherapeutics, Inc. (KR) 2023-12-05 US disclosed
US-7196111-B2 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents SCHERING CORPORATION (US) 2007-03-27 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2006-05-04 US disclosed
EP-1615697-A2 NEW PYRAZOLO[1,5-A] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF NOVO NORDISK A/S (DK) 2006-01-18 EP disclosed
CN-1671710-A Pyrazolo[1,5a]pyrimidine compounds as antiviral agents NEOGENESIS PHARMACEUTICALS INC (US) 2005-09-21 CN disclosed
US-20050187224-A1 Pyrazolopyrimidines BAYER CROPSCIENCE AG (DE) 2005-08-25 US disclosed
EP-1511751-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS Neogenesis Pharmaceuticals, Inc. (US) 2005-03-09 EP disclosed
WO-2004089471-A2 NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF NOVO NORDISK A/S (DK) 2004-10-21 WO disclosed
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents NEOGENESIS PHARMACEUTICALS, INC. 2004-02-26 US disclosed
WO-2003101993-A1 PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS NEOGENESIS PHARMACEUTICALS, INC. (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376108-A1 SALT AND CRYSTAL FORM OF PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF P2RX7, P2RX3, CANX MAPK1 300/4885POLB 4449/4885RAB9A 2503/4885
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 MAPK1 2173/4885POLB 4589/4885RAB9A 3451/4885
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents RNGTT, PNP, ZC3HAV1 MAPK1 2589/4885POLB 70/4885RAB9A 3257/4885
US-20240199623-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS PDE4A, PDE4B, PDE6C MAPK1 2563/4885POLB 1145/4885RAB9A 765/4885
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors CDKN1A, EIF2AK2, DCK MAPK1 280/4885POLB 473/4885RAB9A 3288/4885
US-11834467-B2 Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors IP6K1, MCL1, HIPK1 MAPK1 362/4885POLB 2194/4885RAB9A 1574/4885
US-20050187224-A1 Pyrazolopyrimidines P2RX5, P2RX4, P2RX1 MAPK1 2833/4885POLB 1577/4885RAB9A 2226/4885
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 MAPK1 712/4885POLB 3342/4885RAB9A 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.